The drug is OxyContin — oxycodone hydrochloride extended-release — and it is still prescribed every single day across the United States. FDA-approved in December 1995 and launched by Purdue Pharma in 1996, OxyContin was marketed as a safer, longer-lasting painkiller for chronic pain. That marketing turned out to be one of the most consequential lies in modern medical history. Nearly 727,000 Americans have died from opioid-involved overdoses since 1999, and despite everything we now know, approximately 43.1 million prescriptions for oxycodone-containing products were still dispensed in 2024. For readers of a dementia care and brain health site, this matters more than you might think.
Older adults are among the most frequent recipients of opioid prescriptions for chronic pain conditions, and opioid use in elderly populations has been linked to cognitive decline, increased fall risk, and complications that can mimic or worsen dementia symptoms. This article traces how OxyContin triggered the worst drug crisis in American history, where the crisis stands today, the massive legal settlement finally moving forward in 2025 and 2026, and what families navigating pain management for aging loved ones need to understand about a drug that remains on pharmacy shelves despite its devastating track record. The opioid crisis has also imposed a staggering economic burden — an estimated $2.7 trillion in 2023 alone, according to the White House — touching healthcare systems, families, and communities in ways that ripple far beyond the individuals who become addicted. Understanding this history is not academic. It is practical knowledge for anyone making medical decisions for themselves or someone they care for.
Table of Contents
- How Did OxyContin Become the Drug Behind the Opioid Crisis?
- How Many Opioid Prescriptions Are Still Written Every Day in America?
- The Human Toll — Who Has Paid the Price for the Opioid Crisis?
- What Does the Purdue Pharma Settlement Mean for Victims and Communities?
- Why Is OxyContin Still Prescribed Despite Everything We Know?
- The Economic Weight of the Opioid Crisis on American Healthcare
- Where the Opioid Crisis Goes From Here
- Conclusion
- Frequently Asked Questions
How Did OxyContin Become the Drug Behind the Opioid Crisis?
OxyContin’s rise from a new pharmaceutical product to the catalyst of a national catastrophe was driven by aggressive, deliberately misleading marketing. Purdue Pharma trained its sales representatives to tell physicians that the risk of addiction from OxyContin was “less than one percent” — a claim derived from a tiny, irrelevant study that was never intended to assess addiction potential in the broad patient population. The FDA, for its part, never required abuse-potential trials before granting approval. With that regulatory gap and a sales force armed with false reassurance, prescriptions surged. OxyContin sales exploded from $48 million in 1996 to $1.1 billion by 2000, generating $2.8 billion in revenue from 1995 to 2001. The consequences arrived quickly. Patients prescribed OxyContin for legitimate pain — back injuries, post-surgical recovery, arthritis — found themselves physically dependent within weeks.
The extended-release tablets, when crushed, could deliver a full dose of oxycodone at once, creating a powerful high that fueled both addiction and a black market. Communities in Appalachia and rural America were hit first and hardest, but the crisis eventually reached every demographic and every zip code. By 2012, the U.S. had reached a peak of 260.5 million opioid prescriptions in a single year — enough for roughly four out of every five American adults to have their own bottle. In 2007, Purdue Pharma and three of its executives pleaded guilty to misleading the public, admitting in federal court that the company “with the intent to defraud and mislead” had marketed OxyContin as less addictive than it actually was. The guilty plea resulted in fines, but Purdue continued selling OxyContin. The Sackler family, which owned Purdue, continued collecting billions. For many families who had already lost someone, the plea deal felt less like justice and more like a cost of doing business.
How Many Opioid Prescriptions Are Still Written Every Day in America?
The numbers have come down significantly, but they remain enormous. Approximately 125.7 million opioid prescriptions were dispensed in the United States in 2024. That is a 52 percent decline from the 2012 peak, but it still works out to roughly 344,000 opioid prescriptions filled every single day. The national opioid dispensing rate fell from 46.8 per 100 persons in 2019 to 35.4 per 100 persons in 2024, but geographic disparities are stark. Arkansas leads the nation at 68.8 prescriptions per 100 people, followed by Alabama at 68.5 and Mississippi at 61.4. Hawaii, at 21.0 per 100 persons, and California, at 22.4, sit at the other end of the spectrum. For oxycodone specifically — the active ingredient in OxyContin — about 43.1 million prescriptions were dispensed in 2024, down from approximately 62 million in 2015.
Oxycodone remains one of the two most widely prescribed Schedule II opioids in the country, alongside hydrocodone. The DEA has cut production quotas for oxycodone by over 68 percent since their 2015 peak, which has physically limited supply. However, if you or a loved one is currently prescribed an oxycodone product, these reductions do not automatically mean your prescription is inappropriate — they mean the overall volume being manufactured has been reduced to curb diversion and overprescribing. The important caveat for older adults and dementia caregivers is this: prescribing guidelines have tightened, but pain in elderly patients is real and often undertreated. The pendulum can swing too far in both directions. some patients with genuine chronic pain conditions have been abruptly cut off from medications they depended on, leading to suffering, withdrawal, and in some cases, patients turning to street drugs. The goal is not zero opioid prescriptions — it is appropriate prescribing, careful monitoring, and honest conversations between patients, families, and physicians about both the benefits and the risks.
The Human Toll — Who Has Paid the Price for the Opioid Crisis?
The scale of death is difficult to comprehend. More than 1.3 million Americans have died from drug overdoses since 1999, with nearly 727,000 of those deaths involving opioids. To put that in perspective, it exceeds the number of Americans killed in every war the country has fought since World War I combined. The crisis still kills more than 224 Americans every day, according to the White House. There are signs of progress, though the word feels inadequate given the magnitude of loss. In 2024, the CDC reported 79,384 drug overdose deaths, a 26.2 percent decline from 2023. Preliminary data for the twelve months ending October 2025 shows a further drop to approximately 71,542 deaths, a 17.1 percent decline.
Deaths specifically from prescription opioids like oxycodone peaked at 17,029 in 2017 and declined to 13,026 in 2023. These reductions are meaningful, but they also mask a shift in the crisis itself. The primary killer is no longer the prescription pad — it is illicitly manufactured fentanyl, a synthetic opioid 50 to 100 times more potent than morphine, now contaminating the drug supply and driving the majority of overdose deaths. For families dealing with dementia, the intersection with the opioid crisis is more common than many realize. A person with moderate dementia who was prescribed opioids years ago may still be taking them out of habit or because no one has reassessed the prescription. Cognitive impairment makes it harder for patients to communicate whether the medication is still needed, whether they are experiencing side effects, or whether they are developing dependence. Family caregivers and healthcare proxies should make opioid medication review a regular part of care planning — not to withhold pain relief, but to ensure that what is being prescribed still makes sense for the patient’s current condition.
What Does the Purdue Pharma Settlement Mean for Victims and Communities?
In November 2025, a bankruptcy judge formally approved a $7.4 billion settlement — the culmination of years of litigation against Purdue Pharma and the Sackler family. Under the terms, the Sackler family pays $1.5 billion, and Purdue contributes approximately $900 million in the first tranche, with additional distributions expected in early 2026. All 50 states joined the settlement, and funds are designated for addiction treatment, prevention, and recovery programs over a 15-year period. Approximately $850 million is earmarked for individual victims and their families. The tradeoff at the center of this settlement is one that has divided advocates and survivors since negotiations began.
In exchange for their financial contribution, members of the Sackler family receive certain legal protections from future opioid-related civil lawsuits. For some families, $7.4 billion distributed across 50 states and hundreds of thousands of affected individuals will never feel proportionate to the harm. For others, particularly state attorneys general and public health officials, the settlement represents the fastest path to actual funding for treatment infrastructure that communities desperately need right now. The comparison that keeps coming up: the 1998 tobacco Master Settlement Agreement was worth $206 billion — and tobacco companies survived. Purdue will not. As part of the deal, Purdue Pharma will be dissolved and its assets transferred to Knoa Pharma, an independent foundation tasked with providing opioid-use-disorder treatments and overdose reversal medications.
Why Is OxyContin Still Prescribed Despite Everything We Know?
OxyContin is still on the market because oxycodone, its active ingredient, remains a medically legitimate and sometimes necessary painkiller. Chronic severe pain from cancer, major surgery recovery, or end-stage disease conditions can be debilitating, and for some patients, non-opioid alternatives like NSAIDs, physical therapy, nerve blocks, or acetaminophen are insufficient. The reformulated version of OxyContin, introduced in 2010, is tamper-resistant — it cannot be easily crushed, dissolved, or injected, which reduces (though does not eliminate) its abuse potential. However, the limitations of the current system are real. “Tamper-resistant” does not mean “addiction-proof.” A patient who takes OxyContin exactly as prescribed can still develop physical dependence. Tolerance builds, meaning higher doses are needed over time for the same pain relief, and discontinuation causes withdrawal symptoms.
For elderly patients, especially those with any degree of cognitive impairment, the risks are compounded. Opioids cause sedation, confusion, constipation, and respiratory depression — side effects that overlap with and worsen many dementia-related symptoms. A loved one who becomes more confused or lethargic may be experiencing opioid side effects that get misattributed to dementia progression. The warning for caregivers is straightforward: if an older adult in your care is prescribed any opioid, including oxycodone products, ask the prescribing physician three questions. Is this still necessary? Has a non-opioid alternative been tried? What is the plan for tapering off? These are not confrontational questions. They are standard-of-care questions that too often go unasked, particularly for patients in long-term care facilities where medication reviews can be infrequent.
The Economic Weight of the Opioid Crisis on American Healthcare
The financial cost is almost incomprehensible. In 2023 alone, illicit opioids cost the United States an estimated $2.7 trillion, which represented 9.7 percent of the entire national GDP. Of that figure, 41 percent — roughly $1.1 trillion — was attributed to premature deaths and lost human capital. Another 49 percent, approximately $1.34 trillion, reflected lost quality of life for those living with addiction and their families.
The remaining 10 percent, about $277 billion, covered direct costs including healthcare, criminal justice, and lost workplace productivity. These numbers matter for dementia care because the two crises compete for many of the same resources. Opioid treatment programs, emergency departments, long-term care staff, and Medicaid budgets are all stretched by the opioid epidemic in ways that affect the availability and quality of dementia care. In rural states with the highest opioid dispensing rates — Arkansas, Alabama, Mississippi — these are often the same communities with the fewest neurologists and the longest wait times for memory care.
Where the Opioid Crisis Goes From Here
The crisis is evolving, not ending. While prescription opioid deaths have declined and overall overdose deaths dropped meaningfully in 2024 and 2025, the shift toward illicit fentanyl means the danger has moved outside the doctor’s office and into the unregulated drug supply. The settlement funds from Purdue Pharma and related litigation will begin flowing into state budgets in 2026, but whether that money reaches the communities that need it most — and whether it is spent on evidence-based treatment rather than absorbed into general funds — remains an open and contested question.
For those focused on brain health and dementia care, the forward-looking issue is research. Chronic opioid use has been associated in multiple studies with accelerated cognitive decline, and the generation of Americans who were prescribed opioids at record rates in the 2000s and 2010s is now entering the age range where dementia risk rises sharply. We do not yet fully understand how decades of opioid exposure will interact with Alzheimer’s disease and other dementias, but the early signals suggest that the opioid crisis may leave a cognitive legacy that outlasts the overdose statistics.
Conclusion
OxyContin — the drug Purdue Pharma sold as a safe solution for chronic pain — triggered the deadliest drug crisis in American history. Nearly 727,000 opioid-involved deaths, $2.7 trillion in annual economic damage, and a $7.4 billion settlement later, oxycodone products are still prescribed more than 43 million times a year. The crisis has shifted from prescription pills to illicit fentanyl, but the prescription pipeline that started it all has not been shut off. It has been narrowed, regulated, and reformulated — but not eliminated, because the underlying medical need for effective pain management has not gone away. For dementia caregivers and families navigating brain health decisions, the practical takeaway is vigilance without panic.
Opioids are not inherently evil, but they are inherently risky, especially for older adults with cognitive vulnerabilities. Review medications regularly. Ask hard questions of prescribers. Understand that pain management and cognitive health are not separate concerns — they are deeply intertwined. The opioid crisis taught the country what happens when we trust pharmaceutical marketing over clinical evidence. That lesson applies every time a prescription is written, filled, and taken.
Frequently Asked Questions
Is OxyContin still available at pharmacies?
Yes. OxyContin is still FDA-approved and available by prescription, though it is now reserved for severe chronic pain when non-opioid treatments have failed. A tamper-resistant reformulation was introduced in 2010, and DEA production quotas have been cut by over 68 percent since 2015.
How many people still die from opioid overdoses each day?
More than 224 Americans die from opioid-related causes every day. Preliminary CDC data for the twelve months ending October 2025 shows approximately 71,542 total drug overdose deaths, a significant decline from prior years but still a catastrophic number.
Can opioids cause or worsen dementia symptoms?
Opioids cause sedation, confusion, and cognitive impairment that can mimic or worsen dementia symptoms. Chronic opioid use in older adults has been associated with accelerated cognitive decline in multiple studies. Any new confusion in an older adult taking opioids should prompt a medication review.
What happened to Purdue Pharma?
Purdue Pharma will be dissolved under a $7.4 billion bankruptcy settlement approved in November 2025. Its assets will be transferred to Knoa Pharma, an independent foundation that will provide opioid-use-disorder treatments and overdose reversal medications. The Sackler family, which owned Purdue, is paying $1.5 billion as part of the agreement.
Are prescription opioids still the main driver of overdose deaths?
No. The crisis has shifted to illicitly manufactured fentanyl, which is 50 to 100 times more potent than morphine and now drives the majority of overdose deaths. Prescription opioid deaths peaked at 17,029 in 2017 and declined to 13,026 in 2023.
Should my elderly parent stop taking their opioid prescription immediately?
Never stop opioids abruptly without medical guidance — sudden discontinuation can cause dangerous withdrawal symptoms. Instead, ask the prescribing physician whether the medication is still necessary, whether non-opioid alternatives have been tried, and what a safe tapering plan would look like.
